- PO (Adults and Children
12 yr or 45 kg): Genotype 1, 2, 3, 4, 5, or 6: Treatment-nave with no cirrhosis or with compensated cirrhosis (Child–Pugh A) — Three 100–mg/40–mg tablets once daily for 8 wk or six 50–mg/20–mg pellet packets once daily for 8 wk; Genotype 1: Treatment-experienced with NS5A inhibitor (with no cirrhosis or with compensated cirrhosis [Child–Pugh A]) — Three 100–mg/40–mg tablets once daily for 16 wk or six 50–mg/20–mg pellet packets once daily for 16 wk; Genotype 1: Treatment-experienced with NS3/4A protease inhibitor (with no cirrhosis or with compensated cirrhosis [Child–Pugh A]) — Three 100–mg/40–mg tablets once daily for 12 wk or six 50–mg/20–mg pellet packets once daily for 12 wk; Genotype 1, 2, 4, 5, or 6: Treatment-experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir (no cirrhosis) — Three 100–mg/40–mg tablets once daily for 8 wk or six 50–mg/20–mg pellet packets once daily for 8 wk; Genotype 1, 2, 4, 5, or 6: Treatment-experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir (with compensated cirrhosis [Child–Pugh A]) — Three 100–mg/40–mg tablets once daily for 12 wk or six 50–mg/20–mg pellet packets once daily for 12 wk; Genotype 3: Treatment-experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir (with no cirrhosis or with compensated cirrhosis [Child–Pugh A]) — Three 100–mg/40–mg tablets once daily for 16 wk or six 50–mg/20–mg pellet packets once daily for 16 wk; Liver or kidney transplant recipients — Three 100–mg/40–mg tablets once daily for 12 wk (16 wk for those with Genotype 1 who are treatment experienced with NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor; 16 wk for those with Genotype 3 who are treatment experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir) or six 50–mg/20–mg pellet packets once daily for 12 wk (16 wk for those with Genotype 1 who are treatment experienced with NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor; 16 wk for those with Genotype 3 who are treatment experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir). - PO (Children 3–<12 yr and 30–<45 kg): Genotype 1, 2, 3, 4, 5, or 6: Treatment-nave with no cirrhosis or with compensated cirrhosis (Child–Pugh A) — Five 50–mg/20–mg pellet packets once daily for 8 wk; Genotype 1: Treatment-experienced with NS5A inhibitor (with no cirrhosis or with compensated cirrhosis [Child–Pugh A]) — Five 50–mg/20–mg pellet packets once daily for 16 wk; Genotype 1: Treatment-experienced with NS3/4A protease inhibitor (with no cirrhosis or with compensated cirrhosis [Child–Pugh A]) — Five 50–mg/20–mg pellet packets once daily for 12 wk; Genotype 1, 2, 4, 5, or 6: Treatment-experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir (no cirrhosis) — Five 50–mg/20–mg pellet packets once daily for 8 wk; Genotype 1, 2, 4, 5, or 6: Treatment-experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir (with compensated cirrhosis [Child–Pugh A]) — Five 50–mg/20–mg pellet packets once daily for 12 wk; Genotype 3: Treatment-experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir (with no cirrhosis or with compensated cirrhosis [Child–Pugh A]) — Five 50–mg/20–mg pellet packets once daily for 16 wk; Liver or kidney transplant recipients — Five 50–mg/20–mg pellet packets once daily for 12 wk (16 wk for those with Genotype 1 who are treatment experienced with NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor; 16 wk for those with Genotype 3 who are treatment experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir).
- PO (Children 3–<12 yr and 20–<30 kg): Genotype 1, 2, 3, 4, 5, or 6: Treatment-nave with no cirrhosis or with compensated cirrhosis (Child–Pugh A) — Four 50–mg/20–mg pellet packets once daily for 8 wk; Genotype 1: Treatment-experienced with NS5A inhibitor (with no cirrhosis or with compensated cirrhosis [Child–Pugh A]) — Four 50–mg/20–mg pellet packets once daily for 16 wk; Genotype 1: Treatment-experienced with NS3/4A protease inhibitor (with no cirrhosis or with compensated cirrhosis [Child–Pugh A]) — Four 50–mg/20–mg pellet packets once daily for 12 wk; Genotype 1, 2, 4, 5, or 6: Treatment-experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir (no cirrhosis) — Four 50–mg/20–mg pellet packets once daily for 8 wk; Genotype 1, 2, 4, 5, or 6: Treatment-experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir (with compensated cirrhosis [Child–Pugh A]) — Four 50–mg/20–mg pellet packets once daily for 12 wk; Genotype 3: Treatment-experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir (with no cirrhosis or with compensated cirrhosis [Child–Pugh A]) — Four 50–mg/20–mg pellet packets once daily for 16 wk; Liver or kidney transplant recipients — Four 50–mg/20–mg pellet packets once daily for 12 wk (16 wk for those with Genotype 1 who are treatment experienced with NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor; 16 wk for those with Genotype 3 who are treatment experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir).
- PO (Children 3–<12 yr and <20 kg): Genotype 1, 2, 3, 4, 5, or 6: Treatment-nave with no cirrhosis or with compensated cirrhosis (Child–Pugh A) — Three 50–mg/20–mg pellet packets once daily for 8 wk; Genotype 1: Treatment-experienced with NS5A inhibitor (with no cirrhosis or with compensated cirrhosis [Child–Pugh A]) — Three 50–mg/20–mg pellet packets once daily for 16 wk; Genotype 1: Treatment-experienced with NS3/4A protease inhibitor (with no cirrhosis or with compensated cirrhosis [Child–Pugh A]) — Three 50–mg/20–mg pellet packets once daily for 12 wk; Genotype 1, 2, 4, 5, or 6: Treatment-experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir (no cirrhosis) — Three 50–mg/20–mg pellet packets once daily for 8 wk; Genotype 1, 2, 4, 5, or 6: Treatment-experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir (with compensated cirrhosis [Child–Pugh A]) — Three 50–mg/20–mg pellet packets once daily for 12 wk; Genotype 3: Treatment-experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir (with no cirrhosis or with compensated cirrhosis [Child–Pugh A]) — Three 50–mg/20–mg pellet packets once daily for 16 wk; Liver or kidney transplant recipients — Three 50–mg/20–mg pellet packets once daily for 12 wk (16 wk for those with Genotype 1 who are treatment experienced with NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor; 16 wk for those with Genotype 3 who are treatment experienced with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir).